August Webinar 2022: Dr. William C. Faquin, MD, PhD
Invitation to the 2022 Annual General Meeting
Proposed Agenda
Welcome. Consideration of minutes of last meeting (available in the members area at the IAC website)
Report of the President
Report of the Secretary-Treasurer
a. Proposal of the Nomination Committee for Slate of Directors for 2022 – 2025 (to be accepted by vote)
b. Presentation of accounts (to be accepted by vote)
c. Proposed budget for 2023 (to be accepted by vote)
d. Proposed annual dues for 2023 (to be accepted by vote)
Summary of Strategic Meeting
Report of Cytotechnology Committee
Report of the Continuing Education Committee
Report of the Editor
Report of the Membership Committee
Actions to be approved and discharged:
a. Treasurer
b. Daily Manager
c. Board of Directors
Report on ICC 2022 Baltimore
Miscellaneous Business
Any member may put forward a point for discussion in good time before the meeting. Please send an email to the Freiburg office if you wish to propose an item for Miscellaneous Business.
Looking forward to seeing you on-line.
Fernando Schmitt, MD, FIAC
Secretary-Treasurer, IAC
ICC 2022 in Baltimore
December Webinar 2021: Dr. Sara Monaco
The Central Office has new Rooms
Cytotechnologist Renewal Time
Renewal Timeline
Current Sticker on certificate |
Next sticker due in 4-year cycle |
Date for renewal |
Required Information |
|---|---|---|---|
2017 – 2020 |
2020 – 2023 |
September – December 2020 |
2017 – 2020 |
2018 – 2021 |
2021 – 2024 |
September – December 2021 |
2018 – 2020 |
2019 – 2022 |
2022 – 2025 |
September – December 2022 |
2019 – 2022 |
2020 – 2023 |
2023 – 2026 |
September – December 2023 |
2020 – 2023 |
IAC-IARC Collaboration in Cytology
This standardized approach will include the key diagnostic cytopathological features of each particular lesion or neoplasm, which will improve the quality of diagnosis and reporting and subsequent diagnostic procedures. The reporting systems will include options that will recognize the variations in the availability of diagnostic modalities and management in low- and middle-income countries, where cytopathology is particularly useful and is increasingly available in the absence of histopathological services. These international systems will be able to be used worldwide.
The new publications series will be guided by a Cytopathology Editorial Board, consisting of standing members and experts from around the world. The Board will liaise closely with relevant groups internationally to ensure that areas of overlap are managed proactively.
IARC and the IAC share a specific common interest in the development and expansion of internationally standardized diagnostic reporting of cancer and precancerous disorders worldwide.
The IAC is a scientific, not-for-profit organization of cytopathologists, cytotechnologists, and other professionals dedicated to promoting research in and the practice of clinical cytopathology.
IARC is a not-for-profit, specialized agency of the World Health Organization (WHO). IARC was created to promote international collaborative research on cancer, in order to provide a scientific basis for the adoption of effective strategies for cancer prevention and control. A key activity of IARC is the production of the WHO Classification of Tumours, the international standards for cancer diagnosis, which incorporate data from multiple fields, including epidemiology, radiology, histopathology, cytopathology, and genetics.